ACTG A5142 LOPINAVIR/RITONAVIR PLUS EFAVIRENZ FOR HIV-1 INFECTION

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。比较三个治疗组(1)洛匹那韦/利托那韦加依非韦伦，(2)洛匹那韦/利托那韦加司他夫定缓释（或齐多夫定）加拉米夫定，或(3)依非韦伦加司他夫定缓释（或齐多夫定）加拉米夫定的HIV - 1病毒病毒学失败的时间。两两比较三个治疗组的时间和方案完成情况。方案完成将被定义为病毒学失败或毒性相关的初始随机治疗方案的任何组成部分的停止。比较两组下肢DEXA测量外周脂肪萎缩的发生率。比较各组代谢异常情况。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Compare the time to virologic failure pairwise in HIV 1 between the three treatments groups, (1) Lopinavir/Ritonavir plus Efavirenz, (2) Lopinavir/Ritonavir plus Stavudine Extended Release (or Zidovudine) plus Lamivudine or (3) Efavirenz plus Stavudine Extended Release (or Zidovudine) plus Lamivudine. Compare time to regimen completion pairwise between the 3 treatment groups. Regimen completion will be defined as either virologic failure or toxicity-related discontinuation of any component of the initial randomized treatment regimen. Compare treatment groups occurrence of peripheral lipoatrophy as measured by limb DEXA. Compare groups on metabolic abnormalities.